Postapproval Comparative Safety Study of Tofacitinib and Biological Disease‐Modifying Antirheumatic Drugs: 5‐Year Results from a United States–Based Rheumatoid Arthritis Registry

Postapproval Comparative Safety Study of Tofacitinib and Biological Disease‐Modifying Antirheumatic Drugs: 5‐Year Results from a United States–Based Rheumatoid Arthritis Registry

Objective Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We compared 5‐year adverse event (AE) incidence rates (IRs) between patients initiating tofacitinib and those initiating new biological disease‐modifying antirheumatic drugs (bDMARDs) within the U...

Full description

Bibliographic Details
Main Authors:	Joel M. Kremer, Clifton O. Bingham III, Laura C. Cappelli, Jeffrey D. Greenberg, Ann M. Madsen, Jamie Geier, Jose L. Rivas, Alina M. Onofrei, Christine J. Barr, Dimitrios A. Pappas, Heather J. Litman, Kimberly J. Dandreo, Andrea B. Shapiro, Carol A. Connell, Arthur Kavanaugh
Format:	Article
Language:	English
Published:	Wiley 2021-03-01
Series:	ACR Open Rheumatology
Online Access:	https://doi.org/10.1002/acr2.11232

Similar Items

The progress of postapproval clinical studies on Sabin IPV
by: Li Shi, et al.
Published: (2022-01-01)

Rationales for discontinuation of disease-modifying antirheumatic drugs, biologic agents, and tofacitinib in rheumatoid arthritis
by: Yu. V. Muraviev, et al.
Published: (2018-12-01)

Strengthening postapproval oversight in research ethics committees: Challenges and solutions
by: Yashashri Chandrakant Shetty, et al.
Published: (2023-01-01)

Switching and Discontinuation Pattern of Biologic Disease-Modifying Antirheumatic Drugs and Tofacitinib for Patients With Rheumatoid Arthritis in Taiwan
by: Ko-Jen Li, et al.
Published: (2021-07-01)

Network Meta-Analysis of Tofacitinib, Biologic Disease-Modifying Antirheumatic Drugs, and Apremilast for the Treatment of Psoriatic Arthritis
by: Dafna D. Gladman, MD, et al.
Published: (2020-01-01)

Fracture in clinical studies of tofacitinib in rheumatoid arthritis
by: Karen E. Hansen, et al.
Published: (2022-12-01)

Real-World Comparative Effectiveness of Tofacitinib and Tumor Necrosis Factor Inhibitors as Monotherapy and Combination Therapy for Treatment of Rheumatoid Arthritis
by: George W. Reed, et al.
Published: (2019-11-01)

Tofacitinib Efficacy and Safety in Patients With Ankylosing Spondylitis by Prior Biologic Disease‐Modifying Antirheumatic Drug Use: A Post Hoc Analysis
by: Atul Deodhar, et al.
Published: (2023-12-01)

The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis
by: Dougados, M, et al.
Published: (2022)

Conclusion on the peer review of the pesticide risk assessment of postapproval data submitted for the active substance thiamethoxam
by: European Food Safety Authority
Published: (2012-03-01)

The effect of tofacitinib on residual pain in patients with psoriatic arthritis
by: Dougados, M, et al.
Published: (2020)

The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis
by: Maxime Dougados, et al.
Published: (2022-11-01)

Patient burden and clinical advances associated with postapproval monotherapy cancer drug trials: a retrospective cohort study
by: Benjamin Gregory Carlisle, et al.
Published: (2020-02-01)

Tofacitinib
by: Nilgün Şentürk
Published: (2022-04-01)

Process of drug registration in Israel: the correlation between the number of discussions within the Ministry of Health and postapproval variations by EMA and/or FDA
by: Katerina Shulman, et al.
Published: (2023-05-01)

The expert meeting dedicated to the discussion of results of a local open-label multicenter observational study of the efficiency and safety of tofacitinib in patients with active rheumatoid arthritis with the inefficiency of disease-modifying antirheumatic drugs and to the elaboration of recommendations for the use for tofacitinib in the therapy of rheumatoid arthritis
Published: (2016-10-01)

The expert meeting dedicated to the discussion of results of a local open-label multicenter observational study of the efficiency and safety of tofacitinib in patients with active rheumatoid arthritis with the inefficiency of disease-modifying antirheumatic drugs and to the elaboration of recommendations for the use for tofacitinib in the therapy of rheumatoid arthritis
Published: (2016-01-01)

Use of tofacitinib in real clinical practice to treat patients with rheumatoid arthritis resistant to synthetic and biological disease-modifying antirheumatic drugs: Results of a multicenter observational study
by: D. E. Karateev, et al.
Published: (2016-09-01)

Tofacitinib: Revisión
by: Carlos Ríos Acosta, et al.
Published: (2016-12-01)

Treatment of Multiorgan Sarcoidosis With Tofacitinib
by: William Damsky, et al.
Published: (2020-02-01)

Treatment of Acute Myocardial Infarction and Cardiogenic Shock: Outcomes of the RECOVER III Postapproval Study by Society of Cardiovascular Angiography and Interventions Shock Stage
by: Ivan D. Hanson, et al.
Published: (2024-02-01)

Comparison of treatment effect sizes from pivotal and postapproval trials of novel therapeutics approved by the FDA based on surrogate markers of disease: a meta-epidemiological study
by: Joshua D. Wallach, et al.
Published: (2018-03-01)

Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region
by: Zoltán Kaló, et al.
Published: (2017-01-01)

Tofacitinib for refractory uveitis and scleritis
by: Michael A. Paley, et al.
Published: (2019-03-01)

The effect of tofacitinib on function and quality of life indicators in patients with rheumatoid arthritis resistant to synthetic and biological disease-modifying antirheumatic drugs in real clinical practice: Results of a multicenter observational study
by: D. E. Karateev, et al.
Published: (2017-03-01)

Treatment of experimental amyloidosis with antirheumatic drugs
by: Laima LEONAVIČIENĖ, et al.
Published: (2010-01-01)

Tofacitinib en artritis reumatoide
by: María del Carmen González, et al.
Published: (2017-06-01)

Sex‐Related Differences in Patients at High Bleeding Risk Undergoing Percutaneous Coronary Intervention: A Patient‐Level Pooled Analysis From 4 Postapproval Studies
by: Rishi Chandiramani, et al.
Published: (2020-04-01)

The impact of tofacitinib on fatigue, sleep, and health-related quality of life in patients with rheumatoid arthritis: a post hoc analysis of data from Phase 3 trials
by: Susan J. Bartlett, et al.
Published: (2022-04-01)

Patterns in the Sequential Treatment of Patients With Rheumatoid Arthritis Starting a Biologic or Targeted Synthetic Disease‐Modifying Antirheumatic Drug: 10‐Year Experience From a US‐Based Registry
by: Anton Matsson, et al.
Published: (2024-01-01)

Antirheumatic drugs and COVID-19: frustrations and hopes
by: E. S. Aronova, et al.
Published: (2021-08-01)

The in vitro effect of antirheumatic drugs on platelet function
by: Camilla Brødsgaard Nielsen, et al.
Published: (2020-02-01)

Short story of antirheumatic therapy.VIII. The immunodepressants
by: P. Marson, et al.
Published: (2012-03-01)

Clinical and economic evaluation of the use of biologic disease-modifying antirheumatic drugs and targeted synthetic antirheumatic drugs for ankylosing spondylitis in context of the Russian healthcare system
by: O. I. Ivakhnenko, et al.
Published: (2022-08-01)

The marked and rapid therapeutic effect of tofacitinib in combination with subcutaneous methotrexate in a rheumatoid arthritis patient with poor prognostic factors who is resistant to standard disease-modifying antirheumatic drugs and biologicals: A clinical case
by: N. V. Demidova, et al.
Published: (2016-03-01)

Efficacy and Safety of Tofacitinib in Chinese Patients with Rheumatoid Arthritis
by: Zhan-Guo Li, et al.
Published: (2018-01-01)

Tofacitinib fails to prevent T cell transfer colitis in mice but ameliorates disease activity
by: Sudheendra Hebbar Subramanyam, et al.
Published: (2023-03-01)

One-year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real-world setting: data from a national U.S. rheumatoid arthritis registry
by: Leslie R. Harrold, et al.
Published: (2018-01-01)

Successful Treatment of Chronic Actinic Dermatitis with Tofacitinib
by: Zhong J, et al.
Published: (2024-02-01)

Tofacitinib in Hypertrophic Lichen Planus
by: Peter Seiringer, et al.
Published: (2020-07-01)